These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Trial watch: Genetic association studies link interleukin-6 receptor to coronary heart disease. Harrison C Nat Rev Drug Discov; 2012 Apr; 11(5):342. PubMed ID: 22543459 [No Abstract] [Full Text] [Related]
6. Genetically Proxied IL-6 Receptor Inhibition and Coronary Artery Disease Risk in a Japanese Population. Zhao SS; Gill D Clin Ther; 2024 Aug; 46(8):657-658. PubMed ID: 38821768 [No Abstract] [Full Text] [Related]
7. Interleukin-6: an antagonizing problem becomes a solution. Rettig MB Nat Biotechnol; 1997 Oct; 15(10):952-3. PubMed ID: 9335041 [No Abstract] [Full Text] [Related]
8. Devic disease: translational medicine at work. Rose-John S; Gold R Neurology; 2014 Apr; 82(15):1294-5. PubMed ID: 24634457 [No Abstract] [Full Text] [Related]
9. Treatment of relapsing polychondritis with tocilizumab. Wendling D; Godfrin-Valnet M; Prati C J Rheumatol; 2013 Jul; 40(7):1232. PubMed ID: 23818726 [No Abstract] [Full Text] [Related]
10. Dr. Wallace and Dr. Stone reply. Wallace ZS; Stone JH J Rheumatol; 2013 Jul; 40(7):1232. PubMed ID: 23980261 [No Abstract] [Full Text] [Related]
11. Refractory relapsing polychondritis treated with serial success with interleukin 6 receptor blockade. Wallace ZS; Stone JH J Rheumatol; 2013 Jan; 40(1):100-1. PubMed ID: 23280172 [No Abstract] [Full Text] [Related]
12. Tocilizumab (Actemra) for giant cell arteritis. Med Lett Drugs Ther; 2017 Sep; 59(1530):161-162. PubMed ID: 28922343 [No Abstract] [Full Text] [Related]
13. Interleukin 6 as therapeutic target in athero-/arteriosclerosis--small steps towards a new treatment paradigm in cardiovascular disease? Henry RM Atherosclerosis; 2011 Dec; 219(2):390-1. PubMed ID: 21840523 [No Abstract] [Full Text] [Related]
15. The biology of interleukin-6 in the 21st century. Rose-John S Semin Immunol; 2014 Feb; 26(1):1. PubMed ID: 24556601 [No Abstract] [Full Text] [Related]
16. Interleukin-6 in idiopathic multicentric Castleman's disease after long-term tocilizumab. Akiyama M; Yasuoka H; Takeuchi T Ann Hematol; 2017 Dec; 96(12):2117-2119. PubMed ID: 28861599 [No Abstract] [Full Text] [Related]
17. The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. Schinnerling K; Aguillón JC; Catalán D; Soto L Clin Exp Immunol; 2017 Jul; 189(1):12-20. PubMed ID: 28369786 [TBL] [Abstract][Full Text] [Related]
18. Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. Nakamura I; Omata Y; Naito M; Ito K J Rheumatol; 2009 Feb; 36(2):459-60. PubMed ID: 19208585 [No Abstract] [Full Text] [Related]
19. Is interleukin-6 circulating levels associated with coronary artery disease? Liu C Int J Cardiol; 2012 May; 157(2):270; author reply 253-4. PubMed ID: 22456261 [No Abstract] [Full Text] [Related]
20. Anti-interleukin-6 receptor antibody, tocilizumab, for the treatment of autoimmune diseases. Tanaka T; Narazaki M; Kishimoto T FEBS Lett; 2011 Dec; 585(23):3699-709. PubMed ID: 21419125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]